globalEDGE Business Review

Volume 5, 2011

"Pharmaceutical Counterfeiting in the U.S.: Differentiating Dimensions of the Risk"
by Justin A. Heinonen and Jeremy M. Wilson (Volume 5, Number 1, pp. 1-3, 2011)

Executive Briefing: The creation of a product counterfeiting database highlights variation in known incidents of counterfeit pharmaceuticals across several important dimensions.  By understanding how these incidents differ, researchers can provide empirical insights into the problem, develop evidence-based anti-counterfeit strategy and promote awareness to consumers, government and industry.  This complex form of product counterfeiting involves offending specialists and generalists, has links to terrorist groups and puts the public's health and safety at risk.

"The A-CAPPP Product Counterfeiting Incident Database: A Resource for Advancing Research and Policy"
by Jeremy M. Wilson and Justin A. Heinonen (Volume 5, Number 2, pp. 1-2, 2011)

Executive Briefing: The creation of a national product counterfeiting incident database allows researchers a unique opportunity to generate evidence-based anti-counterfeiting strategy through the analysis of data and evidence.  Integrating the tenets of crime prevention theory and problem analysis, it employs a systematic process to identify U.S.-related incidents of product counterfeiting across industry sectors and compile and code open-source information. The approach establishes the first-ever foundation for continued empirical investigation into the products, perpetrators, victims and criminal justice agencies involved in product counterfeiting.

"Product Counterfeiting in Michigan: Articulating and Mitigating the Risk"
by Jeremy M. Wilson (Volume 5, Number 3, pp. 1-2, 2011)

Executive Briefing: Product counterfeiting in Michigan reflects a growing, global problem, with any trademarked product vulnerable to intellectual property rights violations.  Lacking empirical data on counterfeiting crimes, insights into them remain limited. State policymakers tasked with a local response require evidence-based research to assess the risk of product counterfeiting and to create policies and strategies to it.

"Product Counterfeiting in Australia"
by John Spink (Volume 5, Number 4, pp. 1-2, 2011)

Executive Briefing: Australia faces the same product counterfeiting challenges as the rest of the world. The problem is extremely varied, quickly evolves, is often hard to detect, and provides great challenges in data gathering. Though much of the counterfeit products are manufactured in Asian countries, there is a sizeable amount produced within Australia, with growing evidence of ties to organized crime. The legal framework supports trademarks and intellectual property rights and conviction rates run as high as 80 percent for those who are charged.

"Mainstreaming Fair Trade: From Coffee and Chocolate to Clothing and Beyond"
by Paulette L. Stenzel (Volume 5, Number 5, pp. 1-2, 2011)

Executive Briefing: The Fair Trade movement has expanded around the world in response to public awareness of Fair Trade’s contributions to sustainable development.  In response to public demand, major companies, such as Starbucks and Walmart, have introduced Fair Trade product lines. This article looks at the reasons for those business decisions and to the future of Fair Trade in mainstream business.

"The Health and Economic Effects of Counterfeit Pharmaceuticals in Africa"
by Jeremy M. Wilson and Roy Fenoff (Volume 5, Number 6, pp. 1-2, 2011)

Executive Briefing: Pharmaceutical Counterfeiting in Africa remains a serious threat to quality health care and the African economy. An impairment to public health, counterfeit pharmaceuticals used to combat malaria and tuberculosis have been blamed for up to 700,000 deaths in Africa each year. They reduce the sales of legitimate drugs, reduce tax revenue, deter innovation and growth, discourage foreign investment, and require significant resources to combat them. Without empirical data on the different dimensions of the effects, the sheer magnitude of the problem is currently unknown because the estimates are not very reliable. Greater information on the problem is needed for developing evidence-based policy and decision making.